Bipolar II Disorder: Symptoms, Diagnosis, and Treatment
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
Bipolar II disorder is a mood disorder defined by a lifetime history of at least one hypomanic episode and one major depressive episode, without a history of a full manic episode. Its clinical significance lies in the combination of altered energy and behavior during hypomania with depression that can be severe, recurrent, and disabling. Because hypomania may go unrecognized, many people first seek treatment for depression. Recognizing the full course is essential for choosing safe, appropriate care. National Institute of Mental Health · American Psychiatric Association.
The symptoms of bipolar II form sustained, clinically meaningful mood episodes rather than ordinary daily fluctuations. A professional assessment considers how long each change lasted, what happened to sleep and activity, whether others observed a change, and whether illness, substances, or medication better explain it. Treatment must separately address bipolar depression, elevated or mixed symptoms, relapse prevention, and psychosocial recovery. NIMH · 2023 VA/DoD guideline. For a broader overview of bipolar disorders, see Bipolar Disorder: Symptoms, Types, Diagnosis, and Treatment.
For additional clinical context, see Cyclothymic Disorder: Symptoms, Diagnosis, and Long-Term Course.
What is bipolar II disorder?
Bipolar II is a recognized diagnosis within the bipolar and related disorders classification. DSM-5-TR requires at least one hypomanic episode and at least one major depressive episode; a history of even one full manic episode changes the diagnostic classification. A hypomanic episode involves a distinct, observable shift in mood and energy without the degree of severe impairment, psychosis, or need for hospitalization attributable to mania. The depressive episode, however, can cause major functional impairment. Bipolar II is therefore not simply a mild version of bipolar I. American Psychiatric Association · NIMH. The diagnostic family and its clinical boundaries are mapped in Types of Bipolar Disorder.
Mood may return to an approximately usual baseline between episodes. Other people experience continuing depressive symptoms, disrupted sleep, anxiety, or difficulties in functioning even when a full episode is absent. The diagnosis describes a lifetime pattern, not a fixed personality, an unpredictable temperament, or a continuous state of alternating moods. NIMH · Judd et al., 2003.
Bipolar II symptoms and episode criteria
Hypomanic episodes
Under DSM-5-TR, a hypomanic episode includes a distinct period of abnormally elevated, expansive, or irritable mood and increased activity or energy lasting at least four consecutive days, present most of the day nearly every day. Three or more additional characteristic symptoms are required, or four if the mood is exclusively irritable. The change must be unequivocal and observable by others, and it must differ from usual functioning. Substance effects and medical explanations require clinical consideration. American Psychological Association · American Psychiatric Association. For an episode-specific explanation, see Hypomania: Symptoms, Duration, and Clinical Significance.
Typical signs include elevated self-esteem or grandiosity; unusually little need for sleep without feeling tired; being more talkative or speaking rapidly; racing thoughts; distractibility; increased goal-directed behavior, restlessness, or social activity; and greater participation in risky activities such as imprudent purchases or impulsive sexual decisions. Some people are more irritable than euphoric. A clinician examines the complete combination of symptoms, its duration, and the shift from a person's usual behavior. NIMH symptom guide.
A person may describe hypomania as an unusually productive or enjoyable period. That self-report is important, yet recognition also depends on whether the activity, reduced sleep need, decisions, and behavior changed enough for other people to notice. Enjoying a productive week or occasionally sleeping less because of a deadline does not by itself meet the criteria. Hypomania can also carry real practical costs without meeting the threshold for mania. NIMH · APA.
Major depressive episodes
A major depressive episode lasts at least two weeks and includes depressed mood or markedly diminished interest or pleasure alongside enough additional symptoms to meet the diagnostic threshold. These may include disturbed appetite or weight, insomnia or excessive sleep, fatigue, changes in psychomotor activity, impaired concentration, guilt or worthlessness, and recurrent thoughts of death or suicide. Symptoms must produce meaningful distress or impairment, and other explanations are evaluated. APA bipolar disorders · NIMH.
Bipolar II depression may severely reduce the capacity to work, study, care for oneself, or maintain relationships. During one depressive episode, the clinical presentation may look similar to major depressive disorder. The bipolar II diagnosis depends on the wider lifetime history, especially episodes of hypomania that may never have been discussed during earlier appointments. NIMH diagnostic overview · VA/DoD.
Mixed features, rapid cycling, and psychotic symptoms
Some depressive episodes include concurrent symptoms from the opposite mood pole, such as increased energy, racing thoughts, or pressured speech. Clinicians may apply the mixed-features specifier when the defined criteria are met. These presentations require particular care in assessing risk and treatment strategy. Experiencing several different emotions on the same day is not equivalent to a mixed-features episode. CANMAT/ISBD 2023 · APA. See also Bipolar Disorder With Mixed Features.
Rapid cycling refers to at least four distinct, qualifying mood episodes within a year, under clinically specified separation or polarity-change rules. It is a course descriptor, not a separate illness. Brief mood swings lasting minutes or hours are not automatically rapid cycling. Psychotic symptoms may occur in severe bipolar depression. Psychosis associated with an elevated-mood episode requires reassessment for mania, because psychotic features are incompatible with an episode classified as hypomania. NIMH · APA.
Bipolar II versus bipolar I and cyclothymia
A full manic episode is the defining requirement for bipolar I; a major depressive episode is common but not required for that diagnosis. Bipolar II requires both a major depressive episode and hypomania with no lifetime mania. The two diagnoses cannot be separated merely by how much depression somebody reports or by the degree of creativity or irritability. The determining clinical distinction is the nature of the elevated-mood episode and the person's entire history. NIMH types of bipolar disorder. The diagnostic distinctions are explored further in Bipolar I Disorder: Symptoms, Diagnosis, and Treatment. and Bipolar I vs Bipolar II: Differences in Episodes, Diagnosis, and Course.
Cyclothymic disorder involves an enduring pattern of depressive and hypomanic symptoms that do not reach the full episode criteria that define bipolar II. Other specified and unspecified bipolar-related categories address clinically relevant patterns that do not fulfill the major categories. The phrase bipolar spectrum appears in clinical and research discussions but does not create a substitute diagnostic category based on personality, intuition, or a screening score. NIMH.
Duration, course, and the burden of depression
Four days is the minimum hypomanic duration specified by DSM-5-TR, and two weeks is the minimum for major depression. Actual episodes may continue much longer. Between episodes, symptoms can resolve or persist at a lower intensity. The record of frequency, changes in polarity, ongoing symptoms, and effects on life is more informative than any isolated day of unusual mood. APA · NIMH.
A prospective study by Judd and colleagues evaluated weekly symptoms in 86 people with bipolar II across an average of 13.4 years of follow-up. Depressive symptoms occupied substantially more time than hypomanic symptoms in that cohort. This established observation helps explain why depressive burden deserves sustained attention, while the precise proportion observed in that study is not a forecast for an individual receiving care today. Judd et al., Archives of General Psychiatry.
How bipolar II is diagnosed
Clinical interviews and longitudinal assessment
A clinician takes a detailed history of depressive and elevated periods, changes from baseline functioning, episode duration, associated symptoms, consequences, prior care, family psychiatric history, and possible medical or substance-related causes. Questions often concentrate on periods of unexpectedly high energy that the patient did not initially regard as problematic. With consent, information from a trusted person who witnessed the behavioral changes may help reconstruct the timeline. NICE CG185 · NIMH.
A practical chronological review asks whether the person felt unusually rested after very little sleep, spoke or acted differently, took unfamiliar risks, or displayed an unusually sustained level of energy. It establishes whether such periods happened separately from depression, followed a medication change, or coincided with substance exposure. Clinicians also determine whether an episode ever reached the threshold of mania through major impairment, hospitalization, or psychosis. These details can change the category and the treatment approach. VA/DoD 2023 · APA.
Screening questionnaires are not diagnostic tests
Tools such as the Mood Disorder Questionnaire and Hypomania Checklist can guide discussion about symptoms that deserve further evaluation. Their diagnostic accuracy varies across populations and settings, and people with bipolar II may not recognize or recall hypomanic episodes reliably. A positive screen invites assessment, while a negative one does not conclusively exclude the condition. Neither an internet quiz nor an AI conversation can establish a clinical diagnosis. VA/DoD guideline · NIMH. For instrument-specific limitations, see Bipolar Disorder Screening Tests: MDQ, HCL-32, and Their Limitations.
Physical and medical evaluation
Medical review, examination, and selected laboratory investigations can identify possible contributing conditions, including some thyroid disorders, and establish the baseline necessary for medication safety. There is no single blood test, genetic profile, or brain scan that confirms bipolar II in an individual. Diagnosis is clinical and depends on the best-supported account of episodes, impairment, and differential explanations. NIMH.
Conditions that can resemble bipolar II
Major depressive disorder
Major depression may share the entire depressive symptom presentation with bipolar II. The distinction depends on whether a genuine hypomanic or manic episode has occurred. Missed hypomania is a clinically important reason why initial treatment focused on depression may need reassessment. This difference affects long-term planning and decisions about antidepressants. NIMH · CANMAT/ISBD.
ADHD, anxiety, borderline personality disorder, and OCD
Distractibility, agitation, sleep disturbance, irritability, and impulsivity are shared across several conditions. ADHD symptoms typically begin during development and tend to be relatively persistent, whereas bipolar episodes involve sustained departures from a person's baseline. Anxiety may involve chronic worry and arousal; borderline personality disorder can involve affective instability and interpersonal patterns with different time courses. OCD involves obsessions and compulsions rather than the elevated energy and episode pattern that define bipolar II. More than one condition can coexist, so assessment must address each set of diagnostic criteria. NICE · NIMH.
For a focused comparison of intrusive thoughts, compulsions, and mood episodes, see OCD vs Bipolar Disorder. Assessment of simultaneous conditions is addressed in OCD and Bipolar Disorder.
Substances, medication effects, and medical conditions
Stimulant exposure, some prescription drugs, recreational substances, severe sleep disruption, and medical illness can produce changes in energy and mood. Clinicians establish how symptoms relate to exposure, whether they continue beyond the expected physiological effects, and whether a distinct independent bipolar episode is supported. A sudden change after starting an antidepressant needs clinical assessment, including the possibility of medication-associated activation, rather than automatic reclassification. NIMH · VA/DoD.
Causes and risk factors
Family history, multiple genetic variants, biological processes, environmental stress, and changes in sleep and daily rhythms all contribute to the scientific account of bipolar disorders. A familial vulnerability increases risk but does not establish that an individual will develop bipolar II. Trauma and stress may influence risk or course in some people, yet neither explains every case. Research into neural circuits and circadian systems is relevant, but these findings have not produced an individually reliable laboratory diagnostic test. NIMH causes section.
Treatment of bipolar II: the phase determines the evidence
The goals of treatment include relief of current symptoms, preventing new episodes, supporting everyday functioning, reducing harm, and addressing physical health. Clinicians distinguish acute bipolar depression, emerging hypomania, mixed presentations, and maintenance. Evidence from a trial in acute mania or bipolar I maintenance cannot be treated as proof of efficacy for bipolar II depression. Guidelines, U.S. regulatory indications, medical history, adverse effects, and patient preferences are reviewed together. CANMAT/ISBD 2023 · VA/DoD 2023.
Medications for acute bipolar II depression
The 2023 CANMAT/ISBD update lists quetiapine as the only first-line pharmacological treatment specifically for acute bipolar II depression. Second-line choices include lithium, lamotrigine, lumateperone, electroconvulsive therapy in selected cases, and particular antidepressant strategies with additional limitations. This hierarchy describes the strength of evidence and guideline judgment available at the time; it is not an instruction for someone to start a drug or an assurance that the top-ranked treatment suits all patients. CANMAT/ISBD bipolar II treatment table.
Quetiapine has randomized-study support for bipolar depression that includes bipolar II participants. Its adverse effects may include sedation, dizziness, orthostatic symptoms, weight gain, changes in blood glucose or lipids, and movement-related effects. Monitoring and precautions depend on the individual's clinical risks. Lumateperone has evidence and U.S. regulatory indications involving bipolar I and II depression, but the CANMAT/ISBD panel placed it as second-line specifically for bipolar II because its disorder-specific evidence was more limited when the guideline was prepared. CANMAT/ISBD · NICE monitoring recommendations. · DailyMed quetiapine prescribing information
Lithium and lamotrigine are among guideline-supported options, but clinicians distinguish their use for the acute depressive phase from their roles in long-term maintenance. Lamotrigine's U.S. bipolar approval pertains to maintenance treatment of bipolar I; decisions to use it in bipolar II require attention to evidence, prescribing status, and safety. It is not a treatment for an acute manic emergency. CANMAT/ISBD · FDA prescribing label access.
Antidepressants in bipolar II
Antidepressants need a phase-specific discussion. In selected patients with bipolar II depression without mixed features, CANMAT/ISBD lists sertraline and venlafaxine as second-line options, with monitoring and clinical judgment; adjunctive bupropion has a separate position. These recommendations do not mean that antidepressants are universally effective or safe in all bipolar presentations. Treatment-emergent hypomania, mixed activation, or destabilization requires prompt review. Major guidelines differ in their interpretation of antidepressant monotherapy risks, and an individual's history is crucial. CANMAT/ISBD 2023 · NIMH medications overview.
Changes to antidepressants or other prescribed treatment should be discussed with the prescriber. Rapid shifts in sleep need, energy, impulsivity, or agitation are useful observations to report. Abruptly stopping treatment can create separate medical and relapse risks. NICE.
Hypomania, mixed symptoms, and acute escalation
Care during an emerging hypomanic episode includes assessing judgment, sleep, financial or interpersonal consequences, substance use, medication exposure, and whether symptoms are evolving toward mania. Depending on severity, clinicians may adjust the treatment plan, increase monitoring, enlist agreed support, or arrange specialist care. Psychosis, serious functional loss, inability to care for oneself, or acute safety concerns require urgent assessment. NICE · VA/DoD.
Maintenance treatment
For bipolar II maintenance, CANMAT/ISBD 2023 identifies quetiapine, lithium, and lamotrigine as first-line options. Long-term treatment choice reflects which episodes predominate, the person's previous benefit, side effects, co-occurring conditions, kidney or other organ health, and pregnancy considerations. Relapse prevention includes continuing assessment after an acute episode has resolved. A medication's effectiveness in acute depression should not be assumed to equal its long-term preventive effectiveness. CANMAT/ISBD 2023.
Medication warnings and monitoring
Lithium
Lithium has a narrow therapeutic range and requires laboratory monitoring. Treatment teams monitor blood lithium concentrations, kidney function, thyroid function, and other relevant measures, while considering fluid balance and drug interactions. Dehydration, vomiting, diarrhea, some anti-inflammatory medications, and changes in kidney function can increase toxicity risk. New confusion, pronounced tremor, impaired coordination, or severe gastrointestinal symptoms warrant urgent medical advice. Never change a prescribed lithium regimen without clinical guidance. NICE lithium monitoring. · DailyMed lithium prescribing information
Lamotrigine
Lamotrigine carries a serious skin-rash warning, including the rare possibility of Stevens–Johnson syndrome or toxic epidermal necrolysis. It must be started and increased carefully according to a prescribed titration plan; valproate interactions can raise risk. A new rash or symptoms such as fever or mouth sores should be reported urgently. Interruptions in treatment, pregnancy, and estrogen-containing contraceptives can alter safe management and may require specialist reassessment. NICE · DailyMed label database. · DailyMed lamotrigine prescribing information
Antipsychotics and valproate
Antipsychotic monitoring covers weight, glucose, lipids, blood pressure, sedation, and movement symptoms, according to drug and patient. Valproate has important hepatic, pancreatic, hematologic, and reproductive risks; it is not the routine first-line option for bipolar II depression in the CANMAT/ISBD hierarchy. Pregnancy exposure can cause severe fetal harm, so reproductive plans and safer alternatives require specialist discussion before any treatment change. The adverse-effect profile of one medication should never be generalized to every drug in its class. NICE · CANMAT/ISBD. · DailyMed divalproex prescribing information
Electroconvulsive therapy
ECT may be considered in severe or treatment-resistant bipolar depression or when a rapid response is clinically necessary, including some high-risk situations. It is administered within specialist care with anesthesia and informed consideration of possible cognitive effects. It is distinct from ordinary outpatient psychotherapy and is not a universal next step for bipolar II. CANMAT/ISBD · NIMH.
Psychotherapy and psychosocial treatment
Structured psychoeducation, cognitive behavioral interventions, family-focused therapy, and interpersonal and social rhythm approaches can complement medication. They can improve recognition of early mood changes, strengthen routines, support coping and relationships, and help people plan for recurrence. The treatment plan should match the episode phase, patient preferences, and clinical setting. NIMH psychotherapy · NICE.
Miklowitz and colleagues synthesized randomized evidence for adjunctive psychotherapy in bipolar disorders in a 2021 systematic review and component network meta-analysis. Evidence supports several structured approaches as part of comprehensive care; however, the study pooled varied bipolar populations and interventions. Its overall findings should not be portrayed as proof of identical effects in every person with bipolar II. Miklowitz et al., JAMA Psychiatry.
Family and partner participation should reflect consent, privacy, and appropriate boundaries. Helpful practical support can include noticing a sustained drop in sleep need, arranging an agreed check-in, avoiding conflict escalation, or helping someone attend a planned appointment. Supportive care also considers any independent anxiety disorder, substance-related condition, trauma, or sleep problem. NICE.
Recovery, daily life, and relapse prevention
Many people experience periods of meaningful stability and productive lives with appropriate care. Recovery can involve functioning, relationships, autonomy, physical health, and quality of life as well as symptom remission. Regular appointments remain important because episodes can recur and medication effects require evaluation even when mood has stabilized. NIMH · WHO bipolar disorder fact sheet.
Consistent sleep and waking routines, attention to social rhythms, avoiding problematic substance use, stress-management strategies, and a written early-warning plan can support treatment. Mood records are useful when they show changes from the person's own baseline; they cannot themselves establish an episode or determine which drug to use. Warning signs may include unusual reductions in sleep need, escalating commitments, irritability, impulsive spending, social withdrawal, or returning depressive thinking. NIMH · NICE.
A relapse plan can specify which changes matter, the clinician to contact, how to share observations, steps to reduce foreseeable risks, and what constitutes an emergency. A person and their support network should agree on privacy and practical limits in advance. Long-term treatment adjustments are individualized; suddenly stopping maintenance medication may increase relapse risk. NICE.
Suicide risk and when to seek urgent help
Bipolar disorders are associated with increased suicide risk, particularly during severe depression and some mixed presentations. Suicidal ideas or plans, inability to remain safe, psychosis, major loss of judgment, or an inability to meet basic needs call for prompt professional assessment. In the United States, 988 offers suicide and crisis support by call or text. If danger is immediate, contact emergency services. In other countries, use local emergency and crisis resources. NIMH · 988 Suicide & Crisis Lifeline.
A person previously diagnosed with bipolar II who develops a full manic episode or psychotic symptoms associated with an elevated mood requires urgent reassessment because the diagnosis and treatment may need to change. Clinical urgency is determined by present safety and functional capacity, not by moral judgments about the person. APA · VA/DoD.
Age, pregnancy, and other special circumstances
In adolescents, clinicians distinguish sustained episodic changes from developmentally typical variability and from persistent neurodevelopmental symptoms. Diagnosis may require school and family observations alongside a developmental history. Evidence and medication safety requirements differ from adults. Older people may need additional attention to physical illness, cognition, interactions, kidney function, falls, and side-effect sensitivity. NICE · VA/DoD.
Pregnancy planning and postpartum care require specialist coordination because untreated relapse and medication exposure both matter. Valproate presents particularly serious reproductive concerns; lithium and lamotrigine also require individualized review and monitoring. Pregnancy and lactation are not reasons to independently stop or change prescribed psychiatric medication. General adult trials cannot be transferred uncritically to pregnancy, children, or older adults. NICE.
Common misconceptions
Bipolar II means much more than unpredictable moods. Its definition requires recognizable hypomanic and major depressive episodes over a lifetime. Hypomania need not feel pleasant, and bipolar II need not be less burdensome than bipolar I. Someone may have many symptom-free months or years without the lifetime diagnosis disappearing. Likewise, an isolated screening result does not confer the diagnosis. NIMH · APA.
Medication and psychotherapy have complementary roles, and benefit in one phase cannot be presumed in another. Improvement supports reconsidering goals and monitoring, but treatment changes should be planned with qualified clinicians. Long-term management aims to support a person's autonomy and quality of life, not define every emotional response as a symptom. CANMAT/ISBD · NICE.
Frequently asked questions
Is bipolar II less serious than bipolar I?
Bipolar II has hypomania rather than the full mania that defines bipolar I, but depression in bipolar II can be severe and recurrent. Disability and risk must be assessed individually. The types represent distinct episode patterns rather than a ranking of a person's suffering. NIMH.
Do I need a hypomanic episode to receive a bipolar II diagnosis?
Yes. The defined lifetime combination is at least one hypomanic episode and one major depressive episode without full mania. A clinician may reconsider a previous depression diagnosis when a reliable hypomanic history emerges. APA.
Can someone with bipolar II be stable between episodes?
Yes. Some people return to baseline between episodes, while others have continuing symptoms. Ongoing care considers both acute episodes and residual difficulties. NIMH.
Can bipolar II later be reclassified as bipolar I?
If a person with an earlier bipolar II diagnosis subsequently has a genuine manic episode, the lifetime diagnostic history supports bipolar I. This does not mean everyone with bipolar II progresses to bipolar I. APA.
Can antidepressants be prescribed for bipolar II depression?
In carefully selected nonmixed bipolar II depression, some antidepressants have second-line guideline positions. The choice requires review of mood-switching risks, history, other treatment, and monitoring. Do not initiate or discontinue a prescription without medical guidance. CANMAT/ISBD.
What information should I bring to an assessment?
A timeline of depressive periods and unusually energized or irritable periods is useful, including their duration, changes in sleep need, outside observations, functioning, substances, medication changes, and prior treatment response. Discuss immediate safety concerns directly. NIMH.
Related Articles
References
988 Suicide & Crisis Lifeline. Official crisis support information.
American Psychiatric Association. Bipolar Disorders. Official clinical information.
American Psychological Association. (2022). Diagnosing and treating bipolar spectrum disorders. Monitor on Psychology.
DailyMed. Divalproex sodium delayed-release tablets: U.S. prescribing information. Official drug label.
DailyMed. Lamotrigine: U.S. prescribing information. Official drug label.
DailyMed. Lithium carbonate: U.S. prescribing information. Official drug label.
DailyMed. Quetiapine (Seroquel): U.S. prescribing information. Official drug label.
Judd, L. L., Akiskal, H. S., Schettler, P. J., et al. (2003). A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Archives of General Psychiatry, 60(3), 261–269. DOI: 10.1001/archpsyc.60.3.261.
Keramatian, K., Chithra, N. K., & Yatham, L. N. (2023). The CANMAT and ISBD guidelines for the treatment of bipolar disorder: Summary and a 2023 update of evidence. Focus, 21(4), 344–353. DOI: 10.1176/appi.focus.20230009.
Miklowitz, D. J., Efthimiou, O., Furukawa, T. A., et al. (2021). Adjunctive psychotherapy for bipolar disorder: A systematic review and component network meta-analysis. JAMA Psychiatry, 78(2), 141–150. DOI: 10.1001/jamapsychiatry.2020.2993.
National Institute for Health and Care Excellence. (2014; updated). Bipolar disorder: Assessment and management (CG185). Recommendations.
National Institute of Mental Health. Bipolar Disorder. Clinical overview.
U.S. Department of Veterans Affairs & U.S. Department of Defense. (2023). Clinical Practice Guideline for the Management of Bipolar Disorder. Guideline.
World Health Organization. Bipolar disorder. Official fact sheet.